Alector Shares Are Trading Lower After the Company Released Its INVOKE-2 Phase 2 Trial Results That Failed to Meet Its Primary Endpoint. Also, Bank of America Downgraded the Stock From Neutral to Underperform.
Alector Shares Are Trading Lower After the Company Released Its INVOKE-2 Phase 2 Trial Results That Failed to Meet Its Primary Endpoint. Also, Bank of America Downgraded the Stock From Neutral to Underperform.
Alector的股票在公司发布了未能达到主要终点的INVOKE-2第二阶段试验结果后，交易价格下跌。此外，美国银行将该股票从中立下调至表现不佳。
Alector Shares Are Trading Lower After the Company Released Its INVOKE-2 Phase 2 Trial Results That Failed to Meet Its Primary Endpoint. Also, Bank of America Downgraded the Stock From Neutral to Underperform.
Alector的股票在公司发布其未能达到主要终点的INVOKE-2第二阶段试验结果后交易下跌。此外，美国银行将该股票的评级从中立下调至表现不佳。